404 related articles for article (PubMed ID: 19524963)
21. Denosumab for the management of bone disease in patients with solid tumors.
Body JJ
Expert Rev Anticancer Ther; 2012 Mar; 12(3):307-22. PubMed ID: 22192269
[TBL] [Abstract][Full Text] [Related]
22. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
Martin M; Bell R; Bourgeois H; Brufsky A; Diel I; Eniu A; Fallowfield L; Fujiwara Y; Jassem J; Paterson AH; Ritchie D; Steger GG; Stopeck A; Vogel C; Fan M; Jiang Q; Chung K; Dansey R; Braun A
Clin Cancer Res; 2012 Sep; 18(17):4841-9. PubMed ID: 22893628
[TBL] [Abstract][Full Text] [Related]
23. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
[TBL] [Abstract][Full Text] [Related]
24. New developments for treatment and prevention of bone metastases.
Body JJ
Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
[TBL] [Abstract][Full Text] [Related]
25. Role of denosumab in breast cancer.
Bartsch R; Steger GG
Expert Opin Biol Ther; 2009 Sep; 9(9):1225-33. PubMed ID: 19653867
[TBL] [Abstract][Full Text] [Related]
26. Preventing metastases to bone: denosumab or bisphosphonates?
Nanes MS
J Bone Miner Res; 2010 Mar; 25(3):437-9. PubMed ID: 20200989
[No Abstract] [Full Text] [Related]
27. Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
Smith MR
Urol Oncol; 2008; 26(4):420-5. PubMed ID: 18593621
[TBL] [Abstract][Full Text] [Related]
28. Denosumab dose selection for patients with bone metastases from solid tumors.
Doshi S; Sutjandra L; Zheng J; Sohn W; Peterson M; Jang G; Chow AT; Pérez-Ruixo JJ
Clin Cancer Res; 2012 May; 18(9):2648-57. PubMed ID: 22394983
[TBL] [Abstract][Full Text] [Related]
29. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
[TBL] [Abstract][Full Text] [Related]
30. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma.
Vij R; Horvath N; Spencer A; Taylor K; Vadhan-Raj S; Vescio R; Smith J; Qian Y; Yeh H; Jun S
Am J Hematol; 2009 Oct; 84(10):650-6. PubMed ID: 19714603
[TBL] [Abstract][Full Text] [Related]
31. [Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab].
Tatekoshi A; Sato T; Ibata S; Hashimoto A; Kamihara Y; Horiguchi H; Ono K; Takada K; Iyama S; Takimoto R; Kobune M; Kato J
Rinsho Ketsueki; 2014 Nov; 55(11):2271-6. PubMed ID: 25501406
[TBL] [Abstract][Full Text] [Related]
32. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
33. Safety considerations for use of bone-targeted agents in patients with cancer.
Mortimer JE; Pal SK
Semin Oncol; 2010 Jun; 37 Suppl 1():S66-72. PubMed ID: 20682374
[TBL] [Abstract][Full Text] [Related]
34. Denosumab for treatment of breast cancer bone metastases and beyond.
Nangia JR; Ma JD; Nguyen CM; Mendes MA; Trivedi MV
Expert Opin Biol Ther; 2012 Apr; 12(4):491-501. PubMed ID: 22348344
[TBL] [Abstract][Full Text] [Related]
35. Treatment and prevention of bone complications from prostate cancer.
Lee RJ; Saylor PJ; Smith MR
Bone; 2011 Jan; 48(1):88-95. PubMed ID: 20621630
[TBL] [Abstract][Full Text] [Related]
36. Update on the pharmacological prevention of skeletal-related events in cancer patients.
Kennedy K; Patel H
Orthopedics; 2011 Dec; 34(12):982-5. PubMed ID: 22147215
[TBL] [Abstract][Full Text] [Related]
37. New approaches to treating and preventing bone metastases.
Lipton A
Curr Opin Support Palliat Care; 2010 Sep; 4(3):178-81. PubMed ID: 20703154
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of bone metastasis with anti-RANKL antibody].
Chayahara N; Minami H
Clin Calcium; 2011 Aug; 21(8):1217-22. PubMed ID: 21814028
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer.
Kurata T; Nakagawa K
Jpn J Clin Oncol; 2012 Aug; 42(8):663-9. PubMed ID: 22701037
[TBL] [Abstract][Full Text] [Related]
40. Progress in the treatment of bone metastases in cancer patients.
Mackiewicz-Wysocka M; Pankowska M; Wysocki PJ
Expert Opin Investig Drugs; 2012 Jun; 21(6):785-95. PubMed ID: 22500564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
